
Research ReportTEM
Tempus AI (TEM): Growth Is Real, Profitability Isn’t Yet
Tempus AI is scaling quickly in oncology diagnostics and data licensing, but losses, negative free cash flow, and leverage keep the stock in Hold territory.
Aug 20, 202619 MIN